Ocular Manifestations of Inflammatory Bowel Disease

Ocular Manifestations of Chronic Inflammatory Bowel Disease (IBD): Retrospective Study in the Hepato-gastroenterology Department of the Nancy CHRU

NCT04771039•Central Hospital, Nancy, France

View on ClinicalTrials.gov

Summary

Ocular damage is found in the 3rd rank of extra intestinal manifestations (MEI) Potentially serious functional complications (see uveitis and risk of blindness) requiring rapid management Rare uveitis in the literature (0.5% -3%), study on a large sample to assess their prevalence in patients with IBD at the Nancy CHRU and describe all the ocular manifestations that can be found.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Adult patients followed at Nancy University Hospital for IBD and having consulted in the ophthalmology department

Exclusion Criteria

•Minor patients
•patients without IBD
•patients for whom there is no ophthalmology consultation

Key Dates

Start Date

January 1, 2013

Primary Completion Date

December 1, 2020

Completion Date

December 12, 2020

Last Updated

February 25, 2021

Enrollment

ACTUAL participants

Conditions

Inflammatory Bowel DiseasesOphthalmopathy

Interventions

reason for consultation

OTHER

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

NCT06226883

Inflammatory Bowel DiseasesCrohn's Disease

View study

RECRUITING

Institutional Registry of Rare Diseases

NCT06573723

Rare DiseasesAmyloidosis+24 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 25, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Ocular Manifestations of Inflammatory Bowel Disease

Inclusion Criteria

Exclusion Criteria

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

Institutional Registry of Rare Diseases

Robotic Inflammatory Bowel Disease Development, Learning and Efficacy Study

Feasibility of a Wireless Thermal Capsule Endoscopy to Detect Gastrointestinal Thermal Variance

Clinnova-IBD, a Prospective Cohort of Patients With Inflammatory Bowel Disease (IBD)

Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease